NASDAQ:NEUP Neuphoria Therapeutics Inc. - Common Stock 5/20/2025 Earnings Report $5.53 +0.13 (+2.41%) As of 04:00 PM Eastern Earnings HistoryForecast Neuphoria Therapeutics Inc. - Common Stock EPS ResultsActual EPS$6.55Consensus EPS -$0.47Beat/MissBeat by +$7.02One Year Ago EPSN/ANeuphoria Therapeutics Inc. - Common Stock Revenue ResultsActual Revenue$15.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuphoria Therapeutics Inc. - Common Stock Announcement DetailsQuarterDate5/20/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Neuphoria Therapeutics Inc. - Common Stock Earnings HeadlinesNeuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business UpdatesMay 21 at 6:55 AM | finanznachrichten.deNeuphoria Provides First Quarter 2025 Business UpdatesMay 20 at 4:22 PM | globenewswire.comWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.May 21, 2025 | Priority Gold (Ad)Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comNeuphoria Provides a Review of 2024 and Highlights 2025 PlansApril 15, 2025 | globenewswire.comSee More Neuphoria Therapeutics Inc. - Common Stock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics Inc. - Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics Inc. - Common Stock and other key companies, straight to your email. Email Address About Neuphoria Therapeutics Inc. - Common StockNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.View Neuphoria Therapeutics Inc. - Common Stock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings Autodesk (5/22/2025)Analog Devices (5/22/2025)Copart (5/22/2025)Intuit (5/22/2025)Ross Stores (5/22/2025)Workday (5/22/2025)Toronto-Dominion Bank (5/22/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
